°æ±¸ °íÇü Á¦Á¦(OSD Á¦Á¦) »ê¾÷ÀÇ ¼ºÀå ±âȸ
Growth Opportunities in the Oral Solid Dosage Formulation Industry
»óǰÄÚµå : 1479961
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 73 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,450 £Ü 3,361,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

°³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ¾à¹°Àü´Þ ±â¼ú·Î ¹Ì·¡ ¼ºÀå °¡´É¼ºÀ» ³ôÀδÙ

ÀÌ ºÐ¼®Àº ÇöÀç »ê¾÷ ½Ã³ª¸®¿À, °æÀï ȯ°æ, ±ÔÁ¦ ȯ°æ Æò°¡¸¦ Æ÷ÇÔÇÏ¿© °æ±¸ °íÇü Á¦Á¦(OSD Á¦Á¦) »ê¾÷ÀÇ °³¿ä¿Í ¹ßÀü¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ºÐ¼® ¹üÀ§´Â ºÏ¹Ì(NA), À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC), Áßµ¿ ¹× ¶óƾ¾Æ¸Þ¸®Ä«(LATAM)¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¾÷°è °ü°èÀÚµéÀÌ °æÀï·Â°ú ¼­ºñ½º Á¦°øÀ» °­È­ÇÏ´Â µ¥ ÀÖ¾î °¡Àå ³Î¸® º¸±ÞµÈ ºñÁî´Ï½º ¸ðµ¨°ú ½ÅÈï ºñÁî´Ï½º ¸ðµ¨À» ½Äº°ÇÕ´Ï´Ù. ¾÷°èÀÇ ÁÖ¿ä ÃËÁø ¹× ¾ïÁ¦¿äÀÎ, ÆÄÆ®³Ê½Ê, ÅõÀÚ ¹× ÅëÇÕ È°µ¿, ÆÄ±«Àû ±â¼ú, ÃÖ±Ù ºÎÇüÁ¦ÀÇ ¹ßÀü, ÇöÀç ¹× ¹Ì·¡ µ¿Çâ°ú °ü·ÃÇÏ¿© ¾÷°èÀÇ ¼ºÀå ÀáÀç·ÂÀ» ÆÄ¾ÇÇÕ´Ï´Ù. ¾÷°è »ç¿ë »ç·Ê¿¡¼­´Â ÆÄ±«Àû ±â¼ú ¹× ȯÀÚ Á᫐ ÀǾàǰ °³¹ßÀ» À§ÇØ ³ë·ÂÇϰí ÀÖ´Â °ÔÀÓ Ã¼ÀÎÀú ±â¾÷µé¿¡ ´ëÇÑ °£·«ÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¸Þ°¡Æ®·»µå, ºñÁî´Ï½º ¸ðµ¨, ÀÓ»óÀû ¿ä±¸, »ç¿ë »ç·Ê, ½ÃÀå ÁøÀÔ Àü·«, ±â¼ú µ¿Çâ¿¡ ±â¹ÝÇÑ ¼ºÀå ±âȸ¸¦ ¹ß±¼ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

OSD Á¦Á¦ ¼ºÀå ȯ°æ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â º¯Çõ

»ýŰè

¼ºÀå Á¦³Ê·¹ÀÌÅÍ

¼ºÀå ȯ°æ

Á¤Á¦¡¤Ä¸½¶ ¾÷°è - Çõ½Å°ú Ãֽе¿Çâ

Á¤Á¦¡¤Ä¸½¶ ¾÷°è - Áö¿ª Á¤Ã¥°ú ±ÔÁ¦ÀÇ ¿µÇâ

Á¤Á¦¡¤Ä¸½¶ ¾÷°è - Á¦Á¶¡¤CDMO ¾÷°è °³¿ä

Á¤Á¦¡¤Ä¸½¶ ¾÷°è - ¼ºÀå Å׸¶·Î ¿µÇâÀ» ¹ÌÄ¡´Â ÅõÀÚ µ¿Ç⡤ÅëÇÕ µ¿Çâ

Á¤Á¦¡¤Ä¸½¶ ¾÷°è - Â÷º°È­ ±â¼ú¡¤¼­ºñ½º¿¡ ±â¹ÝÇÑ ±â¾÷ º¥Ä¡¸¶Å·

¼ºÀå ±âȸ À¯´Ï¹ö½º

º£½ºÆ® ÇÁ·¢Æ¼½º ÀνÄ

Frost Radar

´ÙÀ½ ½ºÅÜ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Personalized Medicine and Drug Delivery Technologies Enhance Future Growth Potential

This analysis provides an overview and advancements in the oral solid dosage formulation industry, including an evaluation of the current industry scenario, competitive landscape, and regulatory landscape. The scope of the analysis is global, focusing on North America (NA), Europe, Asia-Pacific (APAC), the Middle East, and Latin America (LATAM). It identifies the most prevalent and emerging business models supporting industry stakeholders in enhancing their competitiveness and service offerings. Discussions on key industry drivers and restraints, partnerships, investment and consolidation activities, disruptive technologies, recent excipient advancements, and present and future trends shed light on the industry's growth potential. Industry use cases will provide brief insights into game-changing participants working toward developing disruptive technologies and patient-centric drugs. The analysis will also help uncover growth opportunities based on megatrends and business models, clinical needs, use cases, market access strategies, and technology trends.

Research Highlights:

Table of Contents

Transformation Impacting the Oral Solid Dosage Formulation Growth Environment

Ecosystem

Growth Generator

Growth Environment

Tablet and Capsule Industry-Innovations and Emerging Trends

Tablet and Capsule Industry-Regional Policies and Regulatory Impact

Tablet and Capsule Industry-Manufacturing and CDMO Industry Overview

Tablet and Capsule Industry-Investment and Consolidation Trends Impacting Growth Themes

Tablet and Capsule Industry-Company Benchmarking based on Differentiated Technologies and Services

Growth Opportunity Universe

Best Practices Recognition

Frost Radar

Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â